Compare Amylx Pharmaceuticals Inc (AMLX) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Zscaler Inc trades at $139.95 (market cap $22.52B). The key difference: Zscaler Inc is far larger — about 11.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | ZS | |
|---|---|---|
Market Cap | $1.98B | $22.52B |
Sector | Health | Technology |
52-Week High | $18.70 | $336.27 |
52-Week Low | $7.64 | $118.05 |
Enterprise Value | $1.70B | $20.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Zscaler (ZS) trades at $139.27, down 5.34% on the day, amid mixed signals. The stock shows strong revenue growth with 2025 revenue reaching $2.67 billion and consistent quarterly EPS beats, but remains unprofitable with a net income margin of -2.44%. Technical indicators are bullish on moving averages but show overbought RSI levels. Recent news highlights class action investigations and AI infrastructure cost pressures, yet analyst sentiment remains overwhelmingly positive with a consensus price target of $192.64.
The outlook for ZS is cautiously optimistic driven by robust cybersecurity demand and AI security traction, but risks include profitability challenges, rising costs, and legal scrutiny. Wall Street maintains a strong buy consensus (79% buy ratings), suggesting significant upside potential if execution improves and margins stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
